Effectiveness of daratumumab therapy in real-life clinical practice in patients with relapsed/refractory multiple myeloma

I n t r o d u c t i o n . Despite the availability and high effectiveness of modern anticancer drugs used to treat patients with multiple myeloma (MM), most patients inevitably develop disease relapses and refractoriness to the ongoing therapy. The prognosis in patients with relapsed MM and refractoriness to the main classes of anticancer drugs (proteasome inhibitors and immunomodulators) remains poor, and the median overall survival (OS) is only 8 months. Daratumumab is the first fully human IgG1-κ monoclonal antibody that binds with high affinity to the CD38 protein on the surface of myeloma cells, has a direct effect on the tumor, and also has an immunomodulatory mechanism of action. In clinical trials, daratumumab has been shown high effective and safety when used as monotherapy in patients with relapsed and double refractory MM.

A i m . To evaluate the effectiveness and safety of daratumumab monotherapy in patients with relapsed/refractory multiple myeloma (RRMM) in real-life clinical practice.

M a t e r i a l s a n d m e t h o d s . We analyzed 32 patients with RRMM (14 men and 18 women) aged 41–76 years (median 65 years) from two hematological centers in the city of Novosibirsk. In 65.6% of patients, stage IIIA according to Durie-Salmon, stage I–II according to the ISS (in 65.6 and 28.1% of patients, respectively), ECOG performance status 0–1 (in 37.5 and 43.7% of patients, respectively) were diagnosed. Bone-related soft tissue plasmacytomas were recorded in 56.3% of patients, high lactate dehydrogenase activity was noted in 12 (37.5%) patients. The median number of prior lines of therapy was 2 (range 2–4). All patients had previously received proteasome inhibitors (bortezomib) and immunomodulatory agents (lenalidomide). Autologous hematopoietic stem cells transplantation was performed in 34.4% of patients. Double refractory MM was registered in 24 (75%) of 32 patients. The median time from diagnosis of MM to initiation of daratumumab therapy was 73.1 months (range 18–144 months). Daratumumab was administered as monotherapy at a dose of 16 mg/kg intravenously weekly (cycles 1–2), every other week (cycles 3–6), and then monthly.

R e s u l t s . The median duration of therapy with daratumumab was 12.2 months (range 4–22 months). The overall response rate (complete response + very good partial response (vgPR) + partial response (PR)) was 67.7%; vgPR – in 9 (29%) patients, PR – in 12 (38.7%), stable disease (SD) was registered in 19.4% of patients, respectively. The median time to response was 3.5 months (range 2.5–6). The median duration of response was 7.9 months (95% confidence interval (CI) 4.7–11.5). The median progression-free survival (PFS) was 19.1 months (95% CI 15.3–23.6), and the 12- and 18-month PFS were 91% and 50%, respectively. The median OS was not reached, and the 12- and 18-month OS values were 100% and 96.3%, respectively. The depth of the response had a statistically significant effect on the PFS (18-month PFS was 100% in the vgPR and PR subgroups and 81% in the SD subgroup, respectively (χ2 = 19.207, p < 0.001)). Therapy with daratumumab was accompanied with a favorable toxicity profile. In 37.5% of patients, grade 1 and 2 infusion reactions were noted, in 6.2% grade ≥ 3, in one patient, therapy was discontinued due to an infusion reaction of the 3rd degree. Fatigue, upper and lower respiratory tract infections (15.6% and 12.5%, respectively), anemia (15.6%), thrombocytopenia (6.2%), and neutropenia (6.2%) were recorded in 15.6% of patients.

C o n c l u s i o n . Therapy with daratumumab is an effective and safe treatment for RRMM.

1. Morandi F., Horenstein A.L., Costa F. et al. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front. Immunol. 2018;9:2722. DOI: 10.3389/fimmu.2018.02722.

2. Usmani S.Z., Weiss B.M., Plesner T. et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44. DOI: 10.1182/blood-2016-03-705210.

3. van de Donk N.W.C.J., Richardson P.G., Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13-29. DOI: 10.1182/blood-2017-06-740944.

4. Usmani S.Z., Diels J., Ito T. et al. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: аn adjusted treatment comparison. Am. J. Hematol. 2017;92(8):E146-E152. DOI: 10.1002/ajh.24781.

5. Usmani S., Ahmadi T., Ng Y. et al. Analysis of realworld data on overall survival in multiple myeloma patients with ≥ 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21(11):1355-1361. DOI: 10.1634/theoncologist.2016-0104.

6. Jelínek T., Mihályová J., Hájek R. CD38 targeted treatment for multiple myeloma. Vnitr Lek. 2018;64(10):939-948. PMID: 30590941.

7. Beksac M., Aydin Y., Goker H. et al. Early access program results from Тurkey and a literature review on daratumumab monotherapy among heavily pretreated patients with relapsed/refractory myeloma. Clin. Lymphoma Myeloma Leuk. 2020;20(8):e474-e484. DOI: 10.1016/j.clml.2020.02.017.

8. de Weers M., Tai Y.T., van der Veer M.S. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. Immunol. 2011;186(3):1840- 1848. DOI: 10.4049/jimmunol.1003032.

9. Overdijk M.B., Verploegen S., Bögels M. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311-321. DOI: 10.1080/19420862.2015.1007813.

10. van Bueren J.L., Jakobs D., Kaldenhoven N. et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474. DOI: 10.1182/blood.V124.21.3474.3474.

11. Krejcik J., Casneuf T., Nijhof I.S. et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394. DOI: 10.1182/blood-2015-12-687749.

12. Lokhorst H.M., Plesner T., Laubach J.P. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 2015;373(13):1207-1219. DOI: 10.1056/NEJMoa1506348.

13. Lonial S., Weiss B.M., Usmani S.Z. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560. DOI: 10.1016/S0140-6736(15)01120-4.

14. McKeage K. Daratumumab: First global approval. Drugs. 2016;76(2):275-281. DOI: 10.1007/s40265-015-0536-1.

15. Chari A., Lonial S., Mark T.M. et al. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 2018;124(22):4342-4349. DOI: 10.1002/cncr.31706.

16. Park S.S., Eom H.S., Kim J.S. et al.; Korean multiple myeloma working party. Brief report: clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. Jpn J. Clin. Oncol. 2019;49(1):92-95. DOI: 10.1093/jjco/hyy177.

17. Salomon-Perzyński A., Walter-Croneck A., Usnarska- Zubkiewicz L. et al. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Adv. Med. Sci. 2019;64(2):349-355. DOI: 10.1016/j.advms.2019.05.001.

18. Cejalvo M.J., Legarda M., Abella E. et al. Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. Br. J. Haematol. 2020;190(5):e289-e292. DOI: 10.1111/bjh.16286.

19. Cook G., Corso A., Streetly M. et al. Daratumumab monotherapy for relapsed or refractory multiple myeloma: results of an early access treatment protocol in Europe and Russia. Oncol. Ther. 2021;9(1):139-151. DOI: 10.1007/s40487-020-00137-x.

20. Lovas S., Varga G., Farkas P. et al. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. Int. J. Hematol. 2019;110(5):559-565. DOI: 10.1007/s12185-019-02715-w.

21. Iida S., Suzuki K., Kusumoto S. et al. Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. Int. J. Hematol. 2017;106(4):541-551. DOI: 10.1007/s12185-017-2281-6.

22. Mateos M.V., Cavo M., Blade J. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132-141. DOI: 10.1016/S0140-6736(19)32956-3.

23. Bahlis N.J., Dimopoulos M.A., White D.J. et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34(7):1875-1884. DOI: 10.1038/s41375-020-0711-6.

24. Facon T., Kumar S., Plesner T. et al.; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 2019;380(22):2104-2115. DOI: 10.1056/NEJMoa1817249.

25. Palumbo A., Chanan-Khan A., Weisel K. et al.; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016;375(8):754-766. DOI: 10.1056/NEJMoa1606038.

26. Dimopoulos M., Quach H., Mateos M.V. et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186-197. DOI: 10.1016/S0140-6736(20)30734-0.

27. Multiple Myeloma. Clinical guidelines. (2021). URL: https://rusoncohem.ru/klinrec/klinicheskie-rekomendaczii-mnozhestvennaya-mieloma/ (accessed 26.04.2023).

28. Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-е548. DOI: 10.1016/S1470-2045(14)70442-5.

29. Mineeva N.V., Krobinets I.I., Bodrova N.N., et al. (2018). Algorithm for the Individual Selection of Bloоd Components and the Detection of Erythrocyte Antigens and Anti-erythrocyte Antibodies in Difficultto-diagnose Cases: Guidelines. Saint Petersburg: ViТ-print, 24 p. (In Russ.)

30. Mendeleeva L.P., Votyakova O.M., Pokrovskaya O.S. et al. National clinical recommendations on diagnosis and treatment of multiple myeloma. Russian Journal of Hematology and Transfusiology. 2014;59(1-S3):2- 24. DOI: 10.18821/0234-5730-2016-61-1. (In Russ.)

31. Bessmeltsev S.S., Karyagina E.V., Ilyushkina E.Yu. et al. Clinical efficacy of daratumumab in monotherapy or relapsed/refractory multiple myeloma. Clinical Oncohematology. 2020;13(1):25-32. DOI: 10.21320/2500-2139-2020-13-1-25-32. (In Russ.)